IL17A and psoriasis: Thus, deucravacitinib is likely to exert its effect mainly by inhibiting JAK2/TYK2-mediated IL-23 signaling and subsequently IL-17 production (120, 121), which is closely linked with psoriasis and PsA pathophysiology.